Stable schizophrenia patients switched to paliperidone palmitate 3-monthly formulation in real life: functioning and resource use

被引：1
|
作者：
Garcia-Portilla, P. [1 ]
Llorca, P. M. [2 ]
Maina, G. [3 ]
Bozikas, V. P. [4 ]
Devrimci-Ozguven, H. [5 ]
Kim, S. W. [6 ]
Bergmans, P. [7 ]
Usankova, I. [8 ]
Cherubin, P. [9 ]
Pungor, K. [10 ]
机构：
[1] Univ Oviedo, Cibersam, Oviedo, Spain
[2] CHR Univ Clermont Ferrand, Pole Psychiat, Clermont Ferrand, France
[3] Univ Torino, SCDU Psichiat, AOU San Luigi Gonzaga, Turin, Italy
[4] Aristotle Univ Thessaloniki, Dept Psychiat, Sch Med, Thessaloniki, Greece
[5] Ankara Univ, Sch Med, Dept Psychiat, Ankara, Turkey
[6] Chonnam Natl Univ, Med Sch, Gwangju, South Korea
[7] Janssen Cilag Biostat & Programming, Biostat & Programming, Breda, Netherlands
[8] Johnson & Johnson, Med Affairs Org, Moscow, Russia
[9] Janssen Cilag, EMEA Med Affairs, Issy Les Moulineaux, France
[10] Janssen Cilag, EMEA Med Affairs, Dusseldorf, Germany
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2019年 / 29卷
关键词：
REMISSION;
D O I：
10.1016/j.euroneuro.2018.11.383
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.272
引用
收藏
页码：S238 / S239
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
    Savitz, A.
    Gopal, S.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuamah, I.
    Wu, C.
    Hough, D.
    Mathews, M.
    Feng, Y.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 201 - 201
  • [32] Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia
    Gopal, Srihari
    Vermeulen, An
    Nandy, Partha
    Ravenstijn, Paulien
    Nuamah, Isaac
    Vidal, Jose Antonio Buron
    Berwaerts, Joris
    Savitz, Adam
    Hough, David
    Samtani, Mahesh N.
    CURRENT MEDICAL RESEARCH AND OPINION, 2015, 31 (11) : 2043 - 2054
  • [33] Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam
    Hough, David
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 198 - 198
  • [34] Comparison of 3-Monthly versus 1-Monthly Paliperidone Palmitate for Time to Onset and Time to Resolution of Extrapyramidal Symptoms in Patients with Exacerbated Schizophrenia
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam
    Hough, David
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 352S - 353S
  • [35] Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
    Mathews, Maju
    Nuamah, Isaac
    Savitz, Adam J.
    Hough, David W.
    Najarian, Dean
    Kim, Edward
    Gopal, Srihari
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2018, 14 : 2807 - 2816
  • [36] Long term impact of 3-monthly paliperidone palmitate on hospitalisation in patients with schizophrenia: Six-year mirror image study
    Clark, Ivana
    Wallman, Phoebe
    Gee, Siobhan
    Taylor, David
    ACTA PSYCHIATRICA SCANDINAVICA, 2024, 150 (01) : 48 - 50
  • [37] Clinical outcomes with paliperidone palmitate 3-monthly injection as monotherapy: observational 3-year follow-up of patients with schizophrenia
    Clark, Ivana
    Wallman, Phoebe
    Gee, Siobhan
    Taylor, David
    EUROPEAN PSYCHIATRY, 2024, 67 (01)
  • [38] PALIPERIDONE PALMITATE 3-MONTHLY COMPARED WITH 1-MONTHLY FORMULATION IN PATIENTS WITH SCHIZOPHRENIA: GLOBAL AND ASIAN SUBPOPULATION ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, NON-INFERIORITY STUDY
    Savitz, A.
    Gopal, S.
    Feng, Y.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuomah, I.
    Ravenstijn, P.
    Wu, C.
    Hough, D.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 : 166 - 167
  • [39] Effectiveness and Quality of Life with Paliperidone Palmitate 3-Monthly in Comparison with Other Long-Acting Drugs
    Di Lorenzo, Rosaria
    Iorio, Anita
    Pinelli, Margherita
    Magarini, Federica
    Marchi, Mattia
    Sacchetti, Andrea
    Calogero, Chiara
    Galeazzi, Gian Maria
    Ferri, Paola
    Rovesti, Sergio
    Minarini, Alessandro
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2022, 18 : 829 - 846
  • [40] Clinical effectiveness of paliperidone palmitate 3-monthly and 1-monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database
    Chiang, Chih-Lin
    Chinen, Madoka
    Daskiran, Mehmet
    Wakamatsu, Akihide
    Turkoz, Ibrahim
    NEUROPSYCHOPHARMACOLOGY REPORTS, 2024, 44 (04) : 716 - 727
12345